Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Outterson

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
The New England Journal of Medicine|November 27, 2024
Azithromycin to Reduce MortalityMaple Goh, Aaron S Kesselheim, Kevin Outterson
Open Forum Infectious Diseases|July 21, 2025
Examining Pricing and Availability for Neglected Tropical Disease Therapies in the United StatesMaple Goh, Kevin Outterson, Aaron S Kesselheim
Health Affairs Scholar|February 19, 2026
Priority without progress: the FDA's neglected tropical disease voucher program after 18 yearsMaple Goh, Kevin Outterson, Aaron S Kesselheim
Lancet (London, England)|September 23, 2024
The time to address the antibiotic pipeline and access crisis is nowManica Balasegaram, Kevin Outterson, John-Arne Røttingen
Nature Reviews. Drug Discovery|October 24, 2020
Improving data sharing to increase the efficiency of antibiotic R&DWes Kim, Kevin Krause, Zak Zimmerman, et al.
The Lancet. Microbe|June 17, 2024
Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for actionMichael Anderson, Adrian Towse, Kevin Outterson, et al.
Nature Reviews. Drug Discovery|October 7, 2017
Market watch: Innovation in the preclinical antibiotic pipelineUrsula Theuretzbacher, Miloje Savic, Christine Årdal, et al.
Nature Reviews. Microbiology|November 21, 2019
The global preclinical antibacterial pipelineUrsula Theuretzbacher, Kevin Outterson, Aleks Engel, et al.
The Lancet. Infectious Diseases|July 25, 2007
Will longer antimicrobial patents improve global public health?Kevin Outterson, Julie Balch Samora, Karen Keller-Cuda
Lancet (London, England)|May 3, 2025
The antimicrobial resistance cube: a framework for identifying policy gaps and driving actionElias Mossialos, Kevin Outterson, Sally Davies, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|November 27, 2024
Azithromycin to Reduce MortalityMaple Goh, Aaron S Kesselheim, Kevin Outterson
Open Forum Infectious Diseases|July 21, 2025
Examining Pricing and Availability for Neglected Tropical Disease Therapies in the United StatesMaple Goh, Kevin Outterson, Aaron S Kesselheim
Health Affairs Scholar|February 19, 2026
Priority without progress: the FDA's neglected tropical disease voucher program after 18 yearsMaple Goh, Kevin Outterson, Aaron S Kesselheim
Lancet (London, England)|September 23, 2024
The time to address the antibiotic pipeline and access crisis is nowManica Balasegaram, Kevin Outterson, John-Arne Røttingen
Nature Reviews. Drug Discovery|October 24, 2020
Improving data sharing to increase the efficiency of antibiotic R&DWes Kim, Kevin Krause, Zak Zimmerman, et al.
The Lancet. Microbe|June 17, 2024
Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for actionMichael Anderson, Adrian Towse, Kevin Outterson, et al.
Nature Reviews. Drug Discovery|October 7, 2017
Market watch: Innovation in the preclinical antibiotic pipelineUrsula Theuretzbacher, Miloje Savic, Christine Årdal, et al.
Nature Reviews. Microbiology|November 21, 2019
The global preclinical antibacterial pipelineUrsula Theuretzbacher, Kevin Outterson, Aleks Engel, et al.
The Lancet. Infectious Diseases|July 25, 2007
Will longer antimicrobial patents improve global public health?Kevin Outterson, Julie Balch Samora, Karen Keller-Cuda
Lancet (London, England)|May 3, 2025
The antimicrobial resistance cube: a framework for identifying policy gaps and driving actionElias Mossialos, Kevin Outterson, Sally Davies, et al.
Pageof 8